PARP inhibition causes synthetic lethality in combination with severe HR deficiency such as of tumor cells from BRCA1 or BRCA2 mutation carriers upon inactivation of the wild‐type allele (Bryant et al., 2005). This evidence concerns the gene BRCA2 and neoplasm.